ALKS
Price
$28.97
Change
+$0.04 (+0.14%)
Updated
Aug 29 closing price
Capitalization
4.78B
53 days until earnings call
VTRS
Price
$10.55
Change
+$0.14 (+1.34%)
Updated
Aug 29 closing price
Capitalization
12.3B
72 days until earnings call
Interact to see
Advertisement

ALKS vs VTRS

Header iconALKS vs VTRS Comparison
Open Charts ALKS vs VTRSBanner chart's image
Alkermes
Price$28.97
Change+$0.04 (+0.14%)
Volume$1.43M
Capitalization4.78B
Viatris
Price$10.55
Change+$0.14 (+1.34%)
Volume$8.62M
Capitalization12.3B
ALKS vs VTRS Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. VTRS commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a StrongBuy and VTRS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (ALKS: $28.97 vs. VTRS: $10.55)
Brand notoriety: ALKS and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 83% vs. VTRS: 97%
Market capitalization -- ALKS: $4.78B vs. VTRS: $12.3B
ALKS [@Pharmaceuticals: Generic] is valued at $4.78B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.3B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 0 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • ALKS’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, ALKS is a better buy in the long-term than VTRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 6 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • ALKS’s TA Score: 6 bullish, 4 bearish.
  • VTRS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than VTRS.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а -2.62% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -0.94% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.55%. For the same industry, the average monthly price growth was +67.47%, and the average quarterly price growth was +80.21%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.55% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($12.3B) has a higher market cap than ALKS($4.78B). VTRS has higher P/E ratio than ALKS: VTRS (236.20) vs ALKS (14.00). ALKS YTD gains are higher at: 0.730 vs. VTRS (-11.977). ALKS has higher annual earnings (EBITDA): 450M vs. VTRS (-493.3M). ALKS has more cash in the bank: 1.02B vs. VTRS (406M). ALKS has less debt than VTRS: ALKS (72.7M) vs VTRS (14.5B). VTRS has higher revenues than ALKS: VTRS (14.1B) vs ALKS (1.51B).
ALKSVTRSALKS / VTRS
Capitalization4.78B12.3B39%
EBITDA450M-493.3M-91%
Gain YTD0.730-11.977-6%
P/E Ratio14.00236.206%
Revenue1.51B14.1B11%
Total Cash1.02B406M250%
Total Debt72.7M14.5B1%
FUNDAMENTALS RATINGS
ALKS vs VTRS: Fundamental Ratings
ALKS
VTRS
OUTLOOK RATING
1..100
1724
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
40100
SMR RATING
1..100
3995
PRICE GROWTH RATING
1..100
5945
P/E GROWTH RATING
1..100
341
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is significantly better than the same rating for ALKS (97) in the Biotechnology industry. This means that VTRS’s stock grew significantly faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (40) in the Biotechnology industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that ALKS’s stock grew somewhat faster than VTRS’s over the last 12 months.

ALKS's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for VTRS (95) in the null industry. This means that ALKS’s stock grew somewhat faster than VTRS’s over the last 12 months.

VTRS's Price Growth Rating (45) in the null industry is in the same range as ALKS (59) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ALKS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for ALKS (34) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than ALKS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSVTRS
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
63%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 9 days ago
67%
Declines
ODDS (%)
Bearish Trend 5 days ago
62%
Bearish Trend 5 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LQIG95.79N/A
N/A
SPDR MarketAxess Inv Grd 400 Corp Bd ETF
CZAR32.21N/A
N/A
Themes Natural Monopoly ETF
QDWN12.19N/A
N/A
Dailydelta Q100 Downside Option Strategy ETF
CCMG30.71-0.03
-0.10%
CCM Global Equity ETF
UFEB35.18-0.07
-0.20%
Innovator US Equity Ultra Bffr ETF™ Feb

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+0.14%
AMRX - ALKS
39%
Loosely correlated
+0.10%
COLL - ALKS
36%
Loosely correlated
+1.17%
PRGO - ALKS
33%
Poorly correlated
+1.15%
PAHC - ALKS
32%
Poorly correlated
-3.61%
PCRX - ALKS
32%
Poorly correlated
-0.67%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+1.34%
ELAN - VTRS
53%
Loosely correlated
-0.54%
ZTS - VTRS
46%
Loosely correlated
+1.04%
AMRX - VTRS
44%
Loosely correlated
+0.10%
EBS - VTRS
39%
Loosely correlated
-1.07%
PAHC - VTRS
38%
Loosely correlated
-3.61%
More